Peptide Initiative

Peptide profile · Weight Management

Setmelanotide

Targeted MC4R agonist for rare genetic obesity caused by melanocortin pathway defects

Strong human trialsFDA approved for this use
~11 hoursHalf-life
~79% subcutaneous bioavailabilityBioavailability
1,117.3Molecular weight, Da

Molecular formula

C49H68N18O9S2

CAS number
920014-72-8
PubChem
11993702
Developed · 2020
Rhythm Pharmaceuticals, Rhythm Pharmaceuticals

Amino acid sequence

Ac-Arg-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys-NH2 (cyclic Cys2-Cys8 disulfide)

Weight ManagementDramatic weight reduction (10-23%) in patients with rare genetic obesity by restoring MC4R-mediated satiety signaling that is absent due to upstream pathway mutations

0.9

Metabolic HealthComprehensive metabolic improvement including BMI reduction, improved lipid profiles, and resolution of hyperphagia-driven metabolic dysfunction

0.8

Quality of LifeTransformative reduction in insatiable hunger (hyperphagia) that characterizes monogenic obesity, dramatically improving daily functioning and psychosocial wellbeing

0.8

Ratings out of 10.

2 – 3mg

Every documented dose level

PhaseDoseFrequency
First 2 weeks2 mgOnce daily
Ongoing maintenance3 mgOnce daily
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for treating obesity caused by confirmed pomc deficiency mutations & managing obesity from pcsk1 or lepr genetic defects

Best for

  • Treating obesity caused by confirmed POMC deficiency mutations

    Setmelanotide is particularly well-suited for individuals focused on treating obesity caused by confirmed pomc deficiency mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Managing obesity from PCSK1 or LEPR genetic defects

    Setmelanotide is particularly well-suited for individuals focused on managing obesity from pcsk1 or lepr genetic defects. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Reducing hyperphagia and body weight in Bardet-Biedl syndrome

    Setmelanotide is particularly well-suited for individuals focused on reducing hyperphagia and body weight in bardet-biedl syndrome. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Addressing early-onset severe obesity with identified melanocortin pathway mutations

    Setmelanotide is particularly well-suited for individuals focused on addressing early-onset severe obesity with identified melanocortin pathway mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

Consider alternatives if

Alternative approaches for weight management supportConsult your healthcare provider for alternatives to Setmelanotide based on your specific needs and medical history
Alternative weight management approachesSemaglutide (Wegovy/Ozempic)Liraglutide (Saxenda)AOD-9604
Non-injectable weight managementOral semaglutide (Rybelsus)Phentermine-topiramate (Qsymia)Lifestyle modifications

Do not use if

  • Known hypersensitivity to setmelanotide or any excipients
  • Obesity not caused by POMC, PCSK1, or LEPR deficiency, Bardet-Biedl syndrome, or acquired hypothalamic obesity
  • Suspected POMC, PCSK1, or LEPR deficiency where genetic testing classifies the variants as benign or likely benign (Bardet-Biedl syndrome and acquired hypothalamic obesity are diagnosed clinically and need no such test)
  • Use during pregnancy (animal studies suggest potential fetal harm)

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Setmelanotide use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Setmelanotide with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Setmelanotide injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Setmelanotide demonstrates favorable tolerability in Phase 3 trials with safety data from over 200 patients across POMC, PCSK1, LEPR-deficient, and Bardet-Biedl syndrome populations.

The most common adverse effect is dose-dependent skin hyperpigmentation (>60% of patients) due to off-target MC1R activation on melanocytes—a manageable, reversible pharmacological effect rather than true toxicity.

Serious psychiatric adverse events including depression and suicidal ideation require baseline mental health screening and ongoing monitoring in all patients .

Safety evidence comes from Phase 3 trials (IMCIVREE, VENTURE) in pediatric and adult populations with confirmed genetic melanocortin pathway defects, with long-term follow-up data supporting chronic administration.

FDA approval in 2020 and EMA approval in 2021 validate the benefit-risk profile in eligible populations.

Acquired hypothalamic obesity has since been added to the FDA-approved indications (label revised 4/2026) ; studies in Prader-Willi syndrome and Alström syndrome continue to characterize safety in other forms of obesity.


Common side effects · experienced by some users

Skin Hyperpigmentation

The most characteristic side effect, occurring in >60% of patients. Results from off-target activation of MC1R on melanocytes. Manifests as generalized darkening of skin that develops gradually over weeks to months.

Management
Expected pharmacological effect of melanocortin receptor activation. Monitor skin changes at regular intervals. Perform baseline and periodic skin examinations including dermoscopy for nevus surveillance. Hyperpigmentation may partially reverse upon treatment discontinuation.

Injection Site Reactions

Local reactions including erythema, pruritus, induration, and mild pain at the injection site. Reported in approximately 20-30% of patients in clinical trials.

Management
Rotate injection sites between abdomen, thigh, and upper arm. Clean site before injection. Apply cold compress if needed. Reactions typically mild and self-limiting.

Nausea

Reported in clinical trials, typically mild to moderate. May be related to central MC4R-mediated effects on appetite and gastrointestinal motility.

Management
Usually resolves with continued treatment. Take with food if helpful. Slow dose titration may reduce incidence.

Diarrhea

Gastrointestinal disturbance reported in some patients, generally mild and transient .

Management
Maintain adequate hydration. Typically self-limiting and does not require dose adjustment.

Serious side effects

Depression and Suicidal Ideation

Cases of depression and suicidal ideation have been reported during clinical trials. Patients should be monitored for neuropsychiatric symptoms, particularly during the first months of treatment .

Management
Screen patients for depression and suicidal ideation before starting treatment. Monitor mood and mental health at each visit. Discontinue if clinically significant depression or suicidal ideation develops. Refer to mental health professional if needed.

Less commonHair Color Darkening and Nevus Changes

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Setmelanotide
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Setmelanotide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeGenetic Counseling — Essential for confirming melanocortin pathway mutations and identifying eligible patients for targeted MC4R agonist therapy
  • SafeBehavioral Therapy — Complementary approach to support dietary and lifestyle modifications alongside pharmacological hunger reduction
  • SafeNutritional Counseling — Supports healthy eating patterns as hyperphagia resolves and appetite normalizes with treatment

With medications

  • CautionOther MC4R Agonists — Redundant mechanism of action with increased risk of melanocortin-related side effects including excessive hyperpigmentation
  • CautionMedications Affecting Melanocortin Signaling — Potential unpredictable interactions with melanocortin pathway signaling and altered efficacy or safety profile
  • CautionPhotosensitizing Agents — May exacerbate skin pigmentation changes and increase risk of melanocytic nevus development in the setting of MC1R activation

With supplements

  • SafeMultivitamins — Generally safe to take alongside Setmelanotide. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs weeks 1-4

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

FDA approved for this use

Onset of effects

Moderate

(1-2 weeks)


How it works

Setmelanotide is a brain hormone activator that works like a master switch for appetite control.

In people with rare genetic defects, this appetite switch gets stuck in the 'on' position, causing extreme hunger and obesity from childhood.

Setmelanotide turns that switch back off by activating the melanocortin-4 receptor in the brain, telling your body to eat less and feel satisfied with smaller meals.

The deeper mechanism

Setmelanotide (RM-493) is a potent, selective agonist of the melanocortin-4 receptor (MC4R), a G-protein coupled receptor expressed predominantly in the paraventricular and dorsomedial hypothalamus.

MC4R activation is critical for appetite suppression and energy expenditure in the leptin-melanocortin signaling pathway.

Setmelanotide directly activates MC4R downstream of POMC neurons, bypassing upstream defects in leptin signaling (LEPR), POMC synthesis (POMC, PCSK1), or leptin signaling intermediates, thereby restoring physiologic appetite suppression in patients with monogenic obesity.

The drug's EC50 for human MC4R is approximately 0.2 nM, making it highly selective and potent.

By activating MC4R on pro-opiomelanocortin (POMC) neurons and other appetite-regulating circuits, setmelanotide reduces hyperphagia, increases satiety, and promotes weight loss specifically in patients with POMC, PCSK1, or LEPR deficiency—conditions that cause severe, treatment-resistant obesity due to leptin-melanocortin pathway dysfunction.


What to expect

  1. Weeks 1-4

    What you might notice

    • Beginning of dose titration from 0
    • 5-1 mg
    • Possible early reduction in hunger intensity
    • Mild injection site reactions
    • Early signs of skin darkening may begin

    What's normal

    • Appetite changes may be subtle initially during low-dose titration
    • Skin hyperpigmentation develops gradually
    • Mild nausea or GI changes are common and usually transient

    What's next

    • Continue dose titration by 0
    • 5 mg every 2 weeks
    • Monitor body weight, hunger scores, and skin changes
    • Target maintenance dose of 2-3 mg
  2. Weeks 4-12

    What you might notice

    • Meaningful reduction in hyperphagia as dose approaches maintenance level
    • Measurable weight loss beginning
    • Skin hyperpigmentation becoming more apparent

    What's normal

    • Hunger reduction is typically the earliest noticeable clinical effect
    • Weight loss follows as caloric intake decreases
    • Skin darkening continues to develop and is an expected pharmacological effect

    What's next

    • Achieve maintenance dose (2-3 mg)
    • Assess clinical response with weight measurements and hyperphagia questionnaires
    • Begin regular dermatological monitoring
  3. Weeks 12-52

    What you might notice

    • Sustained weight loss with many patients achieving >10% body weight reduction
    • Significant and sustained hyperphagia reduction
    • Stable skin pigmentation

    What's normal

    • Weight loss trajectory may vary between genetic subtypes (POMC/PCSK1 patients tend to respond more robustly than LEPR or BBS)
    • Hunger suppression is typically well-maintained
    • Skin changes stabilize

    What's next

    • Continue chronic maintenance therapy
    • Reassess every 3-6 months
    • If <5% weight loss after adequate trial at maximum dose, consider whether to continue
    • Long-term treatment required as weight regain occurs upon discontinuation

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Setmelanotide over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

29 registered studies, 3 still enrolling.

29registered studies
3recruiting now
13phase 3 or 4
11with published results

By phase

Phase 2

9

Phase 3

9

Phase 1

3

Phase 4

3

Phase 2/3

1

Phase 1/2

1

No phase

3

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug

28

Records only

0

About 1,933 people took part in the studies that actually administered Setmelanotide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.


Most recent

  • NCT07496463 Phase 2Enrolling By Invitation1 enrolled

    Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

    Massachusetts General Hospital

  • NCT06760546 Phase 3Recruiting39 enrolled

    A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

    Rhythm Pharmaceuticals, Inc.

  • SETmelanotide to improve hypothalamic function in the ROHHAD-syndrome; a proof of concept study in a small mono-center cohort: the ROH-SET Study

    Universitair Medisch Centrum Utrecht

See all 29 trials for Setmelanotide

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Setmelanotide is named as an intervention; studies that only mention it in passing are not.

Who is eligible for setmelanotide treatment?

Setmelanotide is specifically approved for patients aged 6 years and older with obesity caused by genetically confirmed POMC (proopiomelanocortin) deficiency, PCSK1 (proprotein convertase subtilisin/kexin type 1) deficiency, LEPR (leptin receptor) deficiency, or Bardet-Biedl syndrome. Genetic testing to confirm one of these conditions is required before starting treatment. It is not approved for common (polygenic) obesity.

Why does setmelanotide cause skin darkening?

Setmelanotide activates MC4R to reduce appetite, but it also has some activity at MC1R (melanocortin-1 receptor) on skin melanocytes. MC1R activation stimulates melanin production, leading to skin hyperpigmentation. This is similar to how alpha-MSH (the natural ligand) causes tanning. While setmelanotide has ~20-fold selectivity for MC4R over MC1R, the MC1R effect is sufficient to cause noticeable skin darkening in most patients.

What happens if treatment is stopped?

Setmelanotide addresses the symptom (hyperphagia and obesity) but does not correct the underlying genetic defect. If treatment is discontinued, hyperphagia and weight regain are expected to return as MC4R is no longer being directly stimulated. Long-term, continuous treatment is generally necessary to maintain the benefit.

How is setmelanotide different from GLP-1 receptor agonists like semaglutide?

Setmelanotide works through an entirely different mechanism — it targets the melanocortin-4 receptor (MC4R) in the hypothalamus, which is specific to the leptin-melanocortin appetite pathway. GLP-1 agonists like semaglutide work through the incretin system affecting insulin, glucagon, and gastric emptying. Setmelanotide is uniquely effective in patients with genetic defects in the melanocortin pathway where GLP-1 agonists may be less effective, because the fundamental problem is a disruption in MC4R-mediated satiety signaling.

Can setmelanotide be used in children?

Yes, setmelanotide is approved for patients aged 6 years and older with qualifying genetic obesity conditions. The VENTURE trial specifically studied children aged 2-5 years, showing 83% achieved meaningful BMI reduction with a favorable safety profile. Pediatric dosing starts at 0.5 mg once daily with careful titration.

Is genetic testing required before starting setmelanotide?

Yes, genetic testing confirming POMC, PCSK1, or LEPR deficiency or Bardet-Biedl syndrome is required before treatment. Setmelanotide works by bypassing upstream genetic defects in the melanocortin pathway, so it is only effective when these specific mutations are present. Rhythm Pharmaceuticals offers a free genetic testing program (Uncovering Rare Obesity) to help identify eligible patients.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Setmelanotide, on one page.

Setmelanotide dosing protocol

Medical disclaimer

Setmelanotide is FDA approved for the use described here. It is a prescription medication that should only be started, adjusted, or stopped under the supervision of a qualified healthcare provider. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

2 – 3 mg Once daily · onset 1-2 weeks
Open the Setmelanotide calculatorSetmelanotide calculator